보고서 요약(국문)

시장 개요
전 세계 간세포암 시장은 2022년 9억 7,700만 달러 규모에 달했으며, 2030년까지 24억 달러에 이를 것으로 예상됩니다. 2023년부터 2030년까지 연평균 성장률(CAGR)은 12.2%입니다. 간세포암 시장 동향은 임상 시험 증가와 연구 개발 확대로 인해 간세포암 관련 파이프라인이 크게 성장하고 있음을 보여줍니다.
특히 간내 담관암은 간세포암 시장에서 시장 점유율을 높이는 데 기여했습니다. 예를 들어, 미국 암 협회(American Cancer Society)는 2022년 말까지 원발성 간암 또는 간내 담관암 신규 진단 사례가 약 41,260건, 사망자는 약 30,520명에 이를 것으로 예측했습니다.

간세포암(HCC)의 세계 시장은 조기 진단 및 정확한 진단을 위한 노력 증가, 치료제 파이프라인의 성장, 그리고 활발한 연구 개발 투자 등 여러 요인에 힘입어 확대되고 있습니다. 2022년 8월 17일, 브리스톨 마이어스 스큅(Bristol Myers Squibb)은 터닝 포인트 테라퓨틱스(Turning Point Therapeutics)를 인수하며 정밀 종양학 포트폴리오를 확장했습니다.
시장 동향
간세포암의 조기 진단을 위한 노력 증가가 시장 성장을 견인하고 있습니다.
현재 간세포암 진단에 가장 적합한 방법을 결정하기 위한 여러 임상 시험이 진행 중입니다. 이러한 연구에는 간경변 환자를 대상으로 조영 증강 초음파(CEUS)와 가독세틱산 조영 증강 간 MRI의 진단 성능을 평가하는 연구, 그리고 간 이식 수혜자를 대상으로 다단계 조영 증강 MRI와 CT를 이용한 간세포암 진단의 효과를 비교하는 다기관 전향적 비교 연구 등이 포함됩니다.

차세대 염기서열 분석(NGS)/바이오마커, 분자 영상, 액체 생검, 인공지능과 같은 새로운 진단 기술은 아직 초기 단계에 있기 때문에 연구자들은 환자 치료에 적용하기 위한 비용, 일반화 가능성, 적용상의 어려움 등을 더욱 명확히 정의해야 합니다. 또한 적절한 유전자, 표적, 기술을 식별하는 것도 중요합니다. 각 전략의 장점과 한계를 서로 비교하고 최적의 치료법과 비교하기 위해서는 다기관 전향적 연구가 필요합니다.
기술 발전과 임상 시험의 증가는 제약 회사들에게 수익성 있는 기회를 제공합니다.
주요 기업들은 협력 또는 파트너십을 통해 다양한 연구 및 임상 시험을 진행하고 있으며, 긍정적인 결과를 보여주고 있습니다. 예를 들어, 2022년 1월 18일에는 아시아에서 소라페닙 치료를 받은 적이 있는 진행성 간세포암(HCC) 환자를 대상으로 항PD-1 약물 키트루다(KEYTRUDA)와 최적의 지지 요법(BSC)의 병용 요법을 연구하는 3상 키노트-394(KEYNOTE-394) 임상 시험이 진행되었습니다.

진행성 간세포암(HCC)으로 치료받은 경험이 있는 환자에서 키트루다(KEYTRUDA)와 최적지지요법(BSC) 병용 투여는 위약과 BSC 병용 투여에 비해 사망 위험을 21% 감소시켰습니다. 이러한 전체 생존율(OS) 개선은 통계적으로 유의미하고 임상적으로도 중요한 의미를 가집니다. 머크는 3,000명 이상의 환자를 포함했거나 포함할 것으로 예상되는 7건의 임상 연구로 구성된 전 세계적인 개발 프로그램을 통해 HCC 연구를 더욱 발전시키기 위해 노력하고 있습니다.
진단 방법의 부족과 치료 부작용은 시장 성장을 저해할 것입니다.
그러나 적절한 치료법의 부족과 치료와 관련된 다양한 부작용으로 인해 전 세계 간세포암 시장은 예측 기간 동안 성장이 제한될 수 있습니다. 간암의 증상은 진행된 후에야 나타나는 경우가 많아 조기 발견이 어렵습니다. 간의 대부분은 오른쪽 흉곽에 가려져 있기 때문에 작은 간 종양은 신체 검사에서 발견하기 어려울 수 있습니다.
일부 표적 치료법은 암세포의 신생 혈관 생성을 억제합니다. 다른 치료법은 종양 성장을 촉진하는 특정 암세포 단백질을 표적으로 합니다. 피로, 발진, 식욕 부진, 설사, 통증, 출혈, 손발의 화상, 장 및 위장 천공은 발생 가능한 부작용일 뿐입니다.
COVID-19 영향 분석
COVID-19 분석은 가격 변동, 수요-공급, 정부 정책, 제조업체의 전략적 계획 외에도 COVID-19 이전, COVID-19 기간, COVID-19 이후 시나리오를 고려합니다. 이러한 요인들은 무역 제한, 봉쇄 및 후유증 문제로 인해 공급과 수요의 변동을 야기할 수 있습니다.
러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 전 세계 간세포암 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재 수출입은 예측 기간 동안 전 세계 간세포암 시장 성장에 거의 영향을 미치지 않을 것으로 예상됩니다.

시장 세분화 분석
글로벌 간세포암 시장은 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
화학요법 부문은 채택률 증가로 인해 간세포암 시장 점유율의 약 36.7%를 차지했습니다.
화학요법 부문은 간세포암 시장을 주도했으며, 이러한 추세는 2023년부터 2030년까지 지속될 것으로 예상됩니다. clinicaltrials.gov에 따르면, 18건의 연구가 진행 중이며 예측 기간 동안 완료될 것으로 예상됩니다.
몇 가지 예를 들면, 쑨얏센대학교에서 주관하는 BCLC C 병기 간세포암 환자를 대상으로 소라페닙과 간동맥 내 주입 화학요법 병용 요법의 안전성과 효능을 경동맥 화학색전술과 소라페닙 병용 요법과 비교 평가하는 3상 연구가 있습니다.

후난성 인민병원에서 후원하는 고위험 간세포암 환자를 대상으로 R0 절제 후 고온 복강 내 화학요법 및 표적 치료와 병용한 티슬레리주맙 치료의 안전성 및 유효성 연구가 진행 중이며, 2025년 7월 완료될 예정입니다.
지역 분석
북미는 주요 업체들의 강력한 입지와 기술 발전으로 인해 시장 점유율의 약 37.2%를 차지했습니다.
제조업체들은 북미 지역의 간세포암 치료제 수요 증가로 인해 사업 확장의 기회를 얻고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 빠른 경제 발전으로 인해 암 치료제 생산이 증가하고 있으며, 이는 수요 증가로 이어지고 있습니다.
북미는 다수의 생산자와 공급업체를 보유하고 있으며, 이 지역의 빠른 경제 발전은 간세포암 진단 및 치료에 대한 수요를 촉진하고 있습니다.

암 환자 치료에 사용되는 신제품 출시 증가가 시장 성장을 견인할 것입니다. 기술 발전, 규제 승인 및 신제품 출시 증가 또한 성장을 촉진합니다. 연구자들은 바이오마커와 같은 간세포암에 대한 다양한 치료 접근법에 대한 인식을 높여가고 있으며, 이는 이 지역 시장 확대로 이어지고 있습니다. 이러한 요인들은 북미 시장의 지배력을 보여줍니다.
경쟁 환경
간세포암 시장의 주요 글로벌 기업으로는 Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol Myers Squibb, Bayer AG, Polaris Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Harbour BioMed, Creative Diagnostics 및 Merck & Co. Inc. 등이 있습니다.
보고서 구매 이유

• 치료 유형, 최종 사용자 및 지역별 글로벌 간세포암 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 간세포암 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 간세포암 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Hepatocellular Carcinoma Market reached US$ 977 million in 2022 and is expected to reach US$ 2.4 billion by 2030 and grow with a CAGR of 12.2% during the forecast period 2023-2030. The hepatocellular carcinoma market trends show a large pipeline for hepatocellular carcinoma owing to the rising clinical trials and increasing research and development.
The hepatocellular carcinoma (HCC) market of intrahepatic bile duct has increased the market share for hepatocellular carcinoma. For instance, the American Cancer Society predicted that by the end of 2022, primary liver or intrahepatic bile duct cancer would account for roughly 41,260 new diagnosis cases and around 30,520 fatalities.
The global market for hepatocellular carcinoma is expanding due to factors including the increasing efforts for early and proper diagnosis of HCC, the growing size of the therapeutic pipeline, and high research and development. On August 17, 2022, Bristol Myers Squibb acquired Turning Point Therapeutics, expanding its precision oncology portfolio.
Market Dynamics
Growing Efforts for Early Diagnosis of HCC drive the growth of the Hepatocellular Carcinoma market.
A few clinical trials are currently being conducted to determine the best method for diagnosing hepatocellular carcinomas. These include studies to assess the diagnostic performance of contrast-enhanced ultrasound (CEUS) and gadoxetic acid-enhanced liver MRI among individuals with liver cirrhosis, as well as a multicenter, prospective comparison research of multiphase contrast-enhanced MRI and CT for the detection of hepatocellular carcinoma and liver transplant recipients.
Researchers must further define cost, generalizability, or application logistics for implementation in patient care because newer diagnostic techniques like NGS/biomarkers, molecular imaging, liquid biopsy, and artificial intelligence remain in their early stages. This is in addition to identifying appropriate genes, targets, or techniques. To identify the advantages and restrictions of each strategy when compared to one another and best practice, multi-center prospective studies are required.
Rising Technological Advancements and Clinical Trials creates lucrative opportunities for manufacturers
Various research and clinical trials are being conducted by the major key players in collaboration or partnership, showing positive outcomes. For instance, on January 18, 2022, the anti-PD-1 drug KEYTRUDA and best supportive care (BSC) were investigated in Phase 3 KEYNOTE-394 trial, which was conducted in patients with advanced forms of hepatocellular carcinoma (HCC) who had previously received sorafenib treatment in Asia.
For people previously treated for advanced HCC, KEYTRUDA plus BSC reduced the risk of mortality by 21% compared to placebo plus BSC. This improvement in OS was statistically noteworthy and clinically meaningful. With a worldwide advancement program of seven clinical studies that have included or are anticipated to enroll over 3,000 patients, Merck is committed to furthering research in HCC.
The Lack of Diagnosis Methods and Treatment Side Effects will Hamper the Growth of the Market.
However, the global marketplace for hepatocellular carcinoma may be constrained over the projected period due to the unavailability of proper treatment and various side effects associated with treatment. Because symptoms and signs of liver cancer frequently do not manifest until it is advanced, it can be challenging to detect it early. Because the right rib cage covers most of the liver, small liver tumors can be difficult to find during a physical examination.
Some targeted treatments prevent cancers from growing new blood vessels. Others go after specific cancer cell proteins that promote tumor growth. Fatigue, rash, decreased appetite, diarrhea, soreness, bleeding, scorching of the hands or feet, and holes in the intestine and stomach are only possible side effects.
COVID-19 Impact Analysis
The COVID-19 Analysis considers the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics, Demand-Supply Spectrum, Government Initiatives, and Manufacturers’ Strategic Initiatives. These factors could cause supply and demand to shift due to trading restrictions, lockdowns, and after-effects issues.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global hepatocellular carcinoma market, owing to the low number of key market players in this region. However, the effect of the import and export of raw materials is expected to have little influence over the global hepatocellular carcinoma market growth over the forecast period.
Segment Analysis
The Global Hepatocellular Carcinoma Market is segmented based on treatment type, end user and region.
Owing to Adoption, the Chemotherapy Segment Accounted for Approximately 36.7% of the Hepatocellular Carcinoma Market Share
The chemotherapy segment led the market for hepatocellular carcinoma, and this trend is expected to continue over the projected period 2023-2030. According to clinicaltrials.gov, 18 studies are ongoing and anticipated to be finished during the forecast period.
A few examples include a Phase 3 study sponsored by Sun Yat-sen University to assess the safety and efficacy of Sorafenib in combination with hepatic arterial infusion chemotherapy in comparison with the transarterial chemoembolization combined with Sorafenib in patients having BCLC C stage hepatocellular carcinoma.
A study on the safety and effectiveness of the treatment, Tislelizumab in combination with hyperthermic intraperitoneal chemotherapy and targeted therapy, which is utilized for hepatocellular carcinoma with high-risk, after R0 resection sponsored by the Hunan Provincial People's Hospital and is estimated to be completed by July 2025.
Geographical Analysis
North America Accounted for Approximately 37.2% of the Market Share, Owing to the Strong Presence of Major Players And Increasing Technological Advancements.
Manufacturers have chances to expand their operations in this region because of the rising demand for hepatocellular carcinoma for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of carcinoma therapeutics, increasing demand.
North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, fueling the demand of hepatocellular carcinoma diagnostics and treatment.
Rising new product launches for use in patients with carcinoma will drive market growth. Growth is also fueled by increasing technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various treatment approaches for hepatocellular carcinomas, such as biomarkers, leading to the market expansion in this region. These factors show the dominance of North America.
Competitive Landscape
The major global players in the hepatocellular carcinoma market include Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol Myers Squibb, Bayer AG, Polaris Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Harbour BioMed, Creative Diagnostics and Merck & Co. Inc. among others.
Why Purchase the Report?
• To visualize the Global Hepatocellular Carcinoma Market segmentation based on treatment type, end user and region, and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous hepatocellular carcinoma market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Hepatocellular Carcinoma Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by End User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Efforts for Early Diagnosis of HCC
4.1.1.2. Rising Novel Product Launch and Clinical Trials
4.1.2. Restraints
4.1.2.1. The Lack of Diagnosis Methods and Treatment Side Effects
4.1.3. Opportunity
4.1.3.1. Rising Geriatric Population and Growing Prevalence of Carcinoma
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Chemotherapy *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Brachytherapy
7.4. Local Ablation Therapy
7.5. Surgery
7.6. Others
8. By End User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Ambulatory Surgical Centers
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. The U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. The U.K.
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Eli Lilly and Company *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Teva Pharmaceutical Industries Ltd.
11.3. Bristol Myers Squibb
11.4. Novartis AG
11.5. Bayer AG
11.6. Merck & Co. Inc.
11.7. F. Hoffmann-La Roche Ltd
11.8. Polaris Pharmaceuticals Inc.
11.9. Creative Diagnostics
11.10. Harbour BioMed
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Eli Lilly and Company, 4.	Key Developments, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Novartis AG, Bayer AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Polaris Pharmaceuticals Inc., Creative Diagnostics, Harbour BioMed

표 목록 (Tables)

List of Tables Table 1 Global Hepatocellular Carcinoma Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Hepatocellular Carcinoma Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Hepatocellular Carcinoma Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Hepatocellular Carcinoma Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Hepatocellular Carcinoma Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 6 Global Hepatocellular Carcinoma Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Hepatocellular Carcinoma Market Value, By End User, 2022-2031 (US$ Million)

Table 8 Global Hepatocellular Carcinoma Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Hepatocellular Carcinoma Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Hepatocellular Carcinoma Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 11 North America Hepatocellular Carcinoma Market Value, By End User, 2022-2031 (US$ Million)

Table 12 North America Hepatocellular Carcinoma Market Value, By Country, 2022-2031 (US$ Million)

Table 13 South America Hepatocellular Carcinoma Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 14 South America Hepatocellular Carcinoma Market Value, By End User, 2022-2031 (US$ Million)

Table 15 South America Hepatocellular Carcinoma Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Hepatocellular Carcinoma Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 17 Europe Hepatocellular Carcinoma Market Value, By End User, 2022-2031 (US$ Million)

Table 18 Europe Hepatocellular Carcinoma Market Value, By Country, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Hepatocellular Carcinoma Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Hepatocellular Carcinoma Market Value, By End User, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Hepatocellular Carcinoma Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East & Africa Hepatocellular Carcinoma Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 23 Middle East & Africa Hepatocellular Carcinoma Market Value, By End User, 2022-2031 (US$ Million)

Table 24 Eli Lilly and Company : Overview

Table 25 Eli Lilly and Company : Product Portfolio

Table 26 Eli Lilly and Company : Key Developments

Table 27 Teva Pharmaceutical Industries Ltd.: Overview

Table 28 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 29 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 30 Bristol Myers Squibb: Overview

Table 31 Bristol Myers Squibb: Product Portfolio

Table 32 Bristol Myers Squibb: Key Developments

Table 33 Novartis AG : Overview

Table 34 Novartis AG : Product Portfolio

Table 35 Novartis AG : Key Developments

Table 36 Bayer AG: Overview

Table 37 Bayer AG: Product Portfolio

Table 38 Bayer AG: Key Developments

Table 39 Merck & Co. Inc.: Overview

Table 40 Merck & Co. Inc.: Product Portfolio

Table 41 Merck & Co. Inc.: Key Developments

Table 42 F. Hoffmann-La Roche Ltd: Overview

Table 43F. Hoffmann-La Roche Ltd: Product Portfolio

Table 44 F. Hoffmann-La Roche Ltd: Key Developments

Table 45Polaris Pharmaceuticals Inc.: Overview

Table 46 Polaris Pharmaceuticals Inc.: Product Portfolio

Table 47 Polaris Pharmaceuticals Inc.: Key Developments

Table 48 Creative Diagnostics : Overview

Table 49 Creative Diagnostics : Product Portfolio

Table 50 Creative Diagnostics : Key Developments

Table 51 Harbour BioMed: Overview

Table 52 Harbour BioMed: Product Portfolio

Table 53 Harbour BioMed: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 2 Global Hepatocellular Carcinoma Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 3 Global Hepatocellular Carcinoma Market Share, By End User, 2023 & 2031 (%)

Figure 4 Global Hepatocellular Carcinoma Market Share, By W, 2023 & 2031 (%)

Figure 5 Global Hepatocellular Carcinoma Market Share, By X, 2023 & 2031 (%)

Figure 6 Global Hepatocellular Carcinoma Market Share, By Y, 2023 & 2031 (%)

Figure 7 Global Hepatocellular Carcinoma Market Share, By Z, 2023 & 2031 (%)

Figure 8 Global Hepatocellular Carcinoma Market Share, By Region, 2023 & 2031 (%)

Figure 9 Imaging Tests Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 10 Blood Tests Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 11 Biopsy Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 12 Global Hepatocellular Carcinoma Market Y-o-Y Growth, By Treatment Type, 2023-2031 (%)

Figure 13 Chemotherapy Treatment Type in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 14 Brachytherapy Treatment Type in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 15 Local Ablation Therapy Treatment Type in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 16 Surgery Treatment Type in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 17 Others Treatment Type in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 18 Global Hepatocellular Carcinoma Market Y-o-Y Growth, By End User, 2023-2031 (%)

Figure 19 Hospitals End User in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 20 Specialty Clinics End User in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 21 Ambulatory Surgical Centers End User in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 22 Others End User in Global Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 23 Global Hepatocellular Carcinoma Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 24 North America Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 25 Asia-Pacific Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 26 Europe Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 27 South America Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 28 Middle East and Africa Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 29 North America Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 30 North America Hepatocellular Carcinoma Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 31 North America Hepatocellular Carcinoma Market Share, By End User, 2023 & 2031 (%)

Figure 32 North America Hepatocellular Carcinoma Market Share, By Country, 2023 & 2031 (%)

Figure 33 South America Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 34 South America Hepatocellular Carcinoma Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 35 South America Hepatocellular Carcinoma Market Share, By End User, 2023 & 2031 (%)

Figure 36 South America Hepatocellular Carcinoma Market Share, By Country, 2023 & 2031 (%)

Figure 37 Europe Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 38 Europe Hepatocellular Carcinoma Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 39 Europe Hepatocellular Carcinoma Market Share, By End User, 2023 & 2031 (%)

Figure 40 Europe Hepatocellular Carcinoma Market Share, By Country, 2023 & 2031 (%)

Figure 41 Asia-Pacific Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 42 Asia-Pacific Hepatocellular Carcinoma Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 43 Asia-Pacific Hepatocellular Carcinoma Market Share, By End User, 2023 & 2031 (%)

Figure 44 Asia-Pacific Hepatocellular Carcinoma Market Share, By Country, 2023 & 2031 (%)

Figure 45 Middle East & Africa Hepatocellular Carcinoma Market Value, 2022-2031 (US$ Million)

Figure 46 Middle East & Africa Hepatocellular Carcinoma Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 47 Middle East & Africa Hepatocellular Carcinoma Market Share, By End User, 2023 & 2031 (%)

Figure 48 Eli Lilly and Company : Financials

Figure 49 Teva Pharmaceutical Industries Ltd.: Financials

Figure 50 Bristol Myers Squibb: Financials

Figure 51 Novartis AG : Financials

Figure 52 Bayer AG: Financials

Figure 53 Merck & Co. Inc.: Financials

Figure 54 F. Hoffmann-La Roche Ltd: Financials

Figure 55 Polaris Pharmaceuticals Inc.: Financials

Figure 56 Creative Diagnostics : Financials

Figure 57 Harbour BioMed: Financials

세계 간세포암 시장 – 2023-2030

Global Hepatocellular Carcinoma Market - 2023-2030